form of medication which can be obtained in an efficient manufacturing process that can be used in large scale production while minimizing overall costs.

The present inventors have discovered an anhydrous, *i.e.* non-hydrate, crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole in its free base form, *i.e.* non-salt form, that is considered to possess one or more advantages including, for example, allowing for a more stable, efficient and less expensive large-scale manufacture of pharmaceutical compositions comprising 6-{2-[1-(6-mehyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole. In addition, the inventors have developed useful formulations for delivering the active ingredient, including tablets, capsules, suspensions and other forms.

SUMMARY OF THE INVENTION

In a first aspect, there is provided a compound comprising an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole, wherein the crystalline free base form has a needle-like crystal habit.

In a second aspect, there is provided a pharmaceutical composition comprising the compound as disclosed herein and a pharmaceutically acceptable carrier.

In a third aspect, there is provided a pharmaceutical composition comprising an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole having a needle-like crystal habit, and a suitable pharmaceutical carrier.

In a fourth aspect, there is provided the use of the composition of the third aspect in the manufacture of a medicament for treating a viral infection.

There is provided an anhydrous, *i.e.* non-hydrate, free base crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole (or vapendavir) that will be useful in the treatment of infections including picornavirus infections such as those caused by human rhinovirus or enteroviruses, in treating, alleviating, preventing or reducing the symptoms or exacerbations of asthma or chronic obstructive pulmonary disease (COPD), or in treating, alleviating, preventing or reducing the symptoms of hand, foot and mouth disease.

There is also provided a process for the large-scale manufacture of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole wherein the process comprises the step of forming an anhydrous crystalline free base form of 6-{2-

In one example, the anhydrous crystalline form has a needle-like crystal habit. This differs greatly from other previous versions of vapendavir such as the phosphate salt which has a plate-like crystal habit.

In one exemplary embodiment, the XRPD profile of the anhydrous crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole shows major peaks (2θ) selected from the group consisting of the following approximate values: 4.5, 11.0, 13.6, 20.3, 20.6, 22.1, 23.1, 24.5, and 25.7. In addition, the anhydrous crystalline freebase form of 6-{2-[1-(6-methyl-3-pyridazin7yl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole may have an XRPD profile with peaks (d-spacing,) selected from the group consisting of approximately the following values: 19.5, 8.0, 6.5, 4.4, 4.3, 4.0, 3.8, 3.6, and 3.5.

The XRPD profile of the anhydrous crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole may also have peaks (2θ) selected from the group consisting of the following approximate values: 4.6, 10.4, 11.1, 13.7, 16.1, 16.7, 17.8, 20.4, 20.8, 21.6, 22.1,22.3, 22.4, 23.4, and 24.8. The anhydrous crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole may also have an XRPD profile with peaks (d-spacing,) selected from the group consisting of approximately the following values: 19.2, 8.5, 8.0, 6.5, 5.5, 5.3, 5.0, 4.35, 4.27, 4.12, 4.03, 3.99, 3.96, 3.80 and 3.60.

In one exemplary embodiment of the present ~~invention~~disclosure, the XRPD pattern of the present freebase crystalline form of vapendavir is shown in the attached Figure 1. As indicated in Figure 1, the following peaks were observed:

What is claimed is:

1. A compound comprising an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole.

2. The compound of claim 1, wherein the crystalline free base form has a needle-like crystal habit.

3. The compound of claim 1, wherein the crystalline form has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values: 19.5, 8.0, 6.5, 4.4, 4.3, 4.0, 3.8, 3.6, and 3.5.

4. The compound of claim 1, wherein the crystalline form XRPD peaks (2θ) selected from the group consisting of the following approximate values: 4.5, 11.0, 13.6, 20.3, 20.6, 22.1, 23.1, 24.5, and 25.7.


5. The compound of claim 1, wherein the crystalline form has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values: 19.2, 8.5, 8.0, 6.5, 5.5, 5.3, 5.0, 4.35, 4.27, 4.12, 4.03, 3.99, 3.96, 3.80 and 3.60.

6. The compound of claim 1, wherein the crystalline form XRPD peaks (2θ) selected from the group consisting of the following approximate values: 4.6, 11.1, 13.7, 16.1, 20.4, 20.8, 22.3, and 24.8.

7. The compound of claim 1, wherein the crystalline form has XRPD peaks (2θ) selected from the group consisting of the following approximate values: 4.6, 10.4, 11.1, 13.7, 16.1, 16.7, 17.8, 20.4, 20.8, 21.6, 22.1,22.3, 22.4, 23.4, and 24.8.

8. The compound of claim 1, wherein the crystalline form has the XRPD pattern shown in Figs. 1A, 1B, 2A, 2B or 3.

9. An anhydrous crystalline free base form of the compound of formula (I):



(I)

10. A pharmaceutical composition comprising the compound of any of claims 1-9 and a pharmaceutically acceptable carrier.

11. The pharmaceutical composition of claim 10, wherein the compound of claim 1 is present in an amount of between 20 to 80 percent by weight of the total pharmaceutical composition.

12. The pharmaceutical composition of claim 10, wherein the composition is in the form selected from the group consisting of a tablet, a caplet, a capsule, a suspension, other forms suitable for oral administration, and a suppository.

13. The pharmaceutical composition of claim 10, wherein the composition is in the form of a suspension.


14. The pharmaceutical composition of claim 10, wherein the composition is in the form of a tablet.

15. The pharmaceutical composition of claim 10, wherein the composition is in the form of a resuspendable sachet or powder.


16. The pharmaceutical composition of claim 10, wherein the composition comprises 200-400 mg of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole.

17. A method for manufacturing a crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole comprising the steps of:

a) combining a compound having the formula:



with a compound having the formula:



in a suitable reaction medium to produce the anhydrous free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole having a needle-like crystal habit.

18. The method of claim 17 wherein the reaction medium is an *N*-methylpyrolidine solvent.

19. The method of claim 17 wherein the reaction medium further comprises cesium carbonate and potassium iodide.

20. The method of claim 17, further comprising recrystallizating the 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole in a recrystallization solution.

21. The method of claim 20, wherein the recrystallization solution is ethanol.

22. The method of claim 20, wherein the recrystallization solution is selected from the group consisting of an alcohol, acetone, acetonitrile, dichloromethane, 1,4-dioxane, methyl ethyl ketone, 1-propanol, 2-propanol, tetrahydrofuran, and toluene.

23. The method of claim 20, wherein the recrystallization solution is selected from the group consisting of aqueous mixtures of acetone, acetonitrile, ethanol, 1-propanol and tetrahydrofuran.

24. The method of claim 17, wherein the crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is in a non-hydrateable, anhydrous form.

25. The method of claim 17, wherein 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values: 19.5, 8.0, 6.5, 4.4, 4.3, 4.0, 3.8, 3.6, and 3.5.

26. The method of claim 17, wherein 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole has XRPD peaks (2θ) selected from the group consisting of approximately the following values: 4.5, 11.0, 13.6, 20.3, 20.6, 22.1, 23.1, 24.5, and 25.7.

27. The method of claim 17, wherein 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values: 19.2, 8.5, 8.0, 6.5, 5.5, 5.3, 5.0, 4.35, 4.27, 4.12, 4.03, 3.99, 3.96, 3.80 and 3.60.

28. The method of claim 17, wherein 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole has XRPD peaks (2θ) selected from the group consisting of approximately the following values: 4.6, 10.4, 11.1, 13.7, 16.1, 16.7, 17.8, 20.4, 20.8, 21.6, 22.1,22.3, 22.4, 23.4, and 24.8.

29. The method of claim 17, wherein 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole has XRPD peaks (2θ) selected from the group consisting of approximately the following values: 4.6, 11.1, 13.7, 16.1, 20.4, 20.8, 22.3, and 24.8.

30. The method of claim 17, wherein 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole has the XRPD pattern shown in Figs. 1A, 1B, 2A, 2B or 3.

31. The method of claim 17, further comprising a step of micronizing the 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole.

32. The method of claim 31, wherein the micronized 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole has an average particle size of less than 5 microns.

33. The method of claim 31, wherein the micronization is carried out in combination with the addition of a wetting agent.

34. The method of claim 33, wherein the wetting agent is selected from the group consisting of poloxamer, polysorbate 80, soluplus and povidone.

35. A pharmaceutical composition comprising an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole having a needle-like crystal habit, and a suitable pharmaceutical carrier.

36. The pharmaceutical composition of claim 35, wherein the 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is present in an amount of between 20–80 percent by weight of the total pharmaceutical composition.

37. The pharmaceutical composition of claim 35, wherein the composition is in the form selected from the group consisting of a tablet, a caplet, a capsule, a suspension, other forms suitable for oral administration, and a suppository.

38. The pharmaceutical composition of claim 35, wherein the composition is in the form of a tablet.

39. The pharmaceutical composition of claim 38 wherein the composition comprises the following ingredients:

BTA-798 Free Base (Micronized)	2-3 %
Microcrystalline Cellulose and Carboxymethylcellulose Sodium	1-2%
Xanthan Gum	0.01-1%
Polysorbate 80	0.01-1%
Propylene Glycol	0.1- 2%
Butylparaben	0.001-0.05%
Glycerin	1-10%
Flavor	0.01-.50%
Sucrose	30-50%
0.1M Citric Acid	40-60%

40. The pharmaceutical composition of claim 35, wherein the composition comprises 200 to 400 mg 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole.

41. The pharmaceutical composition of claim 35, wherein the composition comprises 300 mg 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole.

42. The pharmaceutical composition of claim 35, wherein the composition is in the form of a suspension.

43. The pharmaceutical composition of claim 42, wherein the suspension includes buffers, preservatives and/or a viscosity-enhancer.

44. The pharmaceutical composition of claim 42 wherein the suspension comprises the following ingredients:

BTA-798 Free Base (Micronized)	2-3 %
Microcrystalline Cellulose and Carboxymethylcellulose Sodium	1-2%
Xanthan Gum	0.01-1%
Polysorbate 80	0.01-1%
Propylene Glycol	0.1- 2%
Butylparaben	0.001-0.05%
Glycerin	1-10%
Flavor	0.01-.50%
Sucrose	30-50%
0.1M Citric Acid	40-60%

45. The pharmaceutical composition of claim 35, wherein the composition is in the form of a resuspendable sachet or powder.

46. A method of treating a viral infection comprising administering a therapeutically effective amount of the compound of any one of claims 1-9 or the composition of claim 10 or claim 35 to a patient in need of said treatment.

47. The method of claim 46, wherein the compound has a needle-like crystal habit.

48. The method of claim 46, wherein the compound has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values: 19.5, 8.0, 6.5, 4.4, 4.3, 4.0, 3.8, 3.6, and 3.5.

49. The method of claim 46, wherein the compound has XRPD peaks (2θ) selected from the group consisting of approximately the following values: 4.5, 11.0, 13.6, 20.3, 20.6, 22.1, 23.1, 24.5, and 25.7.

50. The method of claim 46, wherein the compound has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values: 19.2, 8.5, 8.0, 6.5, 5.5, 5.3, 5.0, 4.35, 4.27, 4.12, 4.03, 3.99, 3.96, 3.80 and 3.60.

51. The method of claim 46, wherein the compound has XRPD peaks (2θ) selected from the group consisting of approximately the following values: 4.6, 10.4, 11.1, 13.7, 16.1, 16.7, 17.8, 20.4, 20.8, 21.6, 22.1,22.3, 22.4, 23.4, and 24.8.

52. The method of claim 46, wherein the viral infection is a picornavirus.

53. The method of claim 52, wherein the picornavirus is human rhinovirus (HRV).

54. The method of claim 46, wherein the compound is administered in an amount selected from the group consisting of 100 to 1500 mg per day, 300 mg to 1200 mg per day, and from 600 to 1000 mg per day.

55. The method of claim 46, wherein the compound is administered along with a suitable pharmaceutical carrier.

56. A method of treating a viral infection comprising administering a therapeutically effective amount of a compound comprising an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole to a patient in need of said treatment.

57. The method of claim 56, wherein the compound has a needle-like crystal habit.

58. The method of claim 56, wherein the compound has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values: 19.5, 8.0, 6.5, 4.4, 4.3, 4.0, 3.8, 3.6, and 3.5.

59. The method of claim 56, wherein the compound has XRPD peaks (2θ) selected from the group consisting of approximately the following values: 4.5, 11.0, 13.6, 20.3, 20.6, 22.1, 23.1, 24.5, and 25.7.

60. The method of claim 56, wherein the compound has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values:. 19.2, 8.5, 8.0, 6.5, 5.5, 5.3, 5.0, 4.35, 4.27, 4.12, 4.03, 3.99, 3.96, 3.80 and 3.60.

61. The method of claim 56, wherein the compound has XRPD peaks (2θ) selected from the group consisting of approximately the following values: 4.6, 10.4, 11.1, 13.7, 16.1, 16.7, 17.8, 20.4, 20.8, 21.6, 22.1,22.3, 22.4, 23.4, and 24.8.

62. The method of claim 56, wherein the viral infection is a picornavirus.

63. The method of claim 56, wherein the picornavirus is human rhinovirus (HRV).

64. The method of claim 56, wherein the compound is administered in an amount of 0.1 to 1000 mg per day.


65. The method of claim 56, wherein the compound is administered in an amount selected from the group consisting of 100 to 1500 mg per day, 300 mg to 1200 mg per day, and from 600 to 1000 mg per day.

66. The method of claim 56, wherein the compound is administered along with a suitable pharmaceutical carrier.

67. A method of treating a viral infection comprising administering a therapeutically effective amount of the composition of claim 10 to a patient in need of said treatment.

68. A method of treating a viral infection comprising administering a therapeutically effective amount of the composition of claim 35 to a patient in need of said treatment.

69. A compound comprising an anhydrous crystalline free base form of the compound having the formula (I) below:



(I)

70. A pharmaceutical composition comprising the compound of claim 69 and a suitable pharmaceutical carrier.

71. A method of treating a viral infection comprising administering a therapeutically effective amount of the compound of claim 66 to a patient in need of said treatment.

72. A method of treating a viral infection comprising administering a therapeutically effective amount of the composition of claim 70 to a patient in need of said treatment.

73. A method of treating, alleviating, preventing or reducing the symptoms or exacerbations of asthma or chronic obstructive pulmonary disease (COPD) comprising administering a therapeutically effective amount of the compound according to claims 1 to 9 to a patient in need of said treatment.


74. A method of treating, alleviating, preventing or reducing the symptoms or exacerbations of asthma or chronic obstructive pulmonary disease (COPD) comprising administering a therapeutically effective amount of the composition of claim 10 or claim 35 to a patient in need of said treatment.

75. The method of claim 74, wherein the symptom is reduced lung function.


76. A method for manufacturing a crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole comprising

comprising the steps of:

(a) reacting a compound having the formula:



with a compound having the formula:



in a suitable reaction medium to produce the anhydrous free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole having a needle-like crystal habit; and

b) recrystallizating the 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole formed in step (a) in a recrystallization solution.

77. The method of claim 76 further comprising a step of wet milling the recrystallized 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole in a recrystallization solution to produce a free base crystalline form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole having a needle-like crystal habit.

78. The method of claim 77 wherein the wet milling is conducted by recirculation through an in-line pump equipped with a wet milling pump head, followed by heating, cooling, and filtration.

79. The method of claim 76 further comprising a step of micronizing the recrystallized 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole.

80. The method of claim 79 wherein the average particle size of the micronized recrystallized 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is less than five microns.

81. The method of claim 79 wherein the average particle size of the micronized recrystallized 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is from about two to five microns.

82. A method of treating hand foot and mouth disease comprising administering a therapeutically effective amount of the compound according to claims 1 to 9 to a patient in need of said treatment.

83. A method of treating hand foot and mouth disease comprising administering a therapeutically effective amount of the composition of claim 10 or claim 35 to a patient in need of said treatment.

What is claimed is:

1. A compound comprising an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole, wherein the crystalline free base form has a needle-like crystal habit.

2. The compound of claim 1, wherein the crystalline form has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values: 19.5, 8.0, 6.5, 4.4, 4.3, 4.0, 3.8, 3.6, and 3.5.

3. The compound of claim 1, wherein the crystalline form XRPD peaks (2θ) selected from the group consisting of the following approximate values: 4.5, 11.0, 13.6, 20.3, 20.6, 22.1, 23.1, 24.5, and 25.7.

4. The compound of claim 1, wherein the crystalline form has XRPD peaks (d-space, Å) selected from the group consisting of approximately the following values: 19.2, 8.5, 8.0, 6.5, 5.5, 5.3, 5.0, 4.35, 4.27, 4.12, 4.03, 3.99, 3.96, 3.80 and 3.60.

5. The compound of claim 1, wherein the crystalline form XRPD peaks (2θ) selected from the group consisting of the following approximate values: 4.6, 11.1, 13.7, 16.1, 20.4, 20.8, 22.3, and 24.8.

6. The compound of claim 1, wherein the crystalline form has XRPD peaks (2θ) selected from the group consisting of the following approximate values: 4.6, 10.4, 11.1, 13.7, 16.1, 16.7, 17.8, 20.4, 20.8, 21.6, 22.1,22.3, 22.4, 23.4, and 24.8.

7. The compound of claim 1, wherein the crystalline form has the XRPD pattern shown in Figs. 1A, 1B, 2A, 2B or 3.

8. A pharmaceutical composition comprising the compound of any of claims 1-7 and a pharmaceutically acceptable carrier.

9. The pharmaceutical composition of claim 8, wherein the composition is in the form selected from the group consisting of a tablet, a caplet, a capsule, a suspension, other forms suitable for oral administration, and a suppository.

10. The pharmaceutical composition of claim 8, wherein the composition is in the form of a suspension.

11. The pharmaceutical composition of claim 8, wherein the composition is in the form of a tablet.

12. The pharmaceutical composition of claim 8, wherein the composition is in the form of a resuspendable sachet or powder.

13. The pharmaceutical composition of claim 8, wherein the composition comprises 200-400 mg of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole.

14. A pharmaceutical composition comprising an anhydrous crystalline free base form of 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole having a needle-like crystal habit, and a suitable pharmaceutical carrier.

15. The pharmaceutical composition of claim 14, wherein the 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole is present in an amount of between 20–80 percent by weight of the total pharmaceutical composition.

16. The pharmaceutical composition of claim 14, wherein the composition is in the form selected from the group consisting of a tablet, a caplet, a capsule, a suspension, other forms suitable for oral administration, and a suppository.

17. The pharmaceutical composition of claim 14, wherein the composition is in the form of a tablet.

18. The pharmaceutical composition of claim 17 wherein the composition comprises the following ingredients:

BTA-798 Free Base (Micronized)	2-3 %
Microcrystalline Cellulose and Carboxymethylcellulose Sodium	1-2%
Xanthan Gum	0.01-1%
Polysorbate 80	0.01-1%
Propylene Glycol	0.1- 2%
Butylparaben	0.001-0.05%
Glycerin	1-10%
Flavor	0.01-.50%
Sucrose	30-50%
0.1M Citric Acid	40-60%

19. The pharmaceutical composition of claim 14, wherein the composition comprises 200 to 400 mg 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole.

20. The pharmaceutical composition of claim 14, wherein the composition comprises 300 mg 6-{2-[1-(6-methyl-3-pyridazinyl)-4-piperidinyl]ethoxy}-3-ethoxy-1,2-benzoxazole.

21. The pharmaceutical composition of claim 14, wherein the composition is in the form of a suspension.

22. The pharmaceutical composition of claim 21, wherein the suspension includes buffers, preservatives and/or a viscosity-enhancer.

23. The pharmaceutical composition of claim 21 wherein the suspension comprises the following ingredients:

BTA-798 Free Base (Micronized)	2-3 %
Microcrystalline Cellulose and Carboxymethylcellulose Sodium	1-2%
Xanthan Gum	0.01-1%
Polysorbate 80	0.01-1%
Propylene Glycol	0.1- 2%
Butylparaben	0.001-0.05%
Glycerin	1-10%
Flavor	0.01-.50%
Sucrose	30-50%
0.1M Citric Acid	40-60%

24. The pharmaceutical composition of claim 14, wherein the composition is in the form of a resuspendable sachet or powder.

25. Use of the composition of any one of claims 14-24 in the manufacture of a medicament for treating a viral infection.